SABCS 2022 | Key data at SABCS 2022

Susan Dent, MD, FRCPC, Duke University School of Medicine, Durham, NC, talks on key data presented at the San Antonio Breast Cancer Symposium (SABCS) 2022, including on antibody-drug conjugates (ADCs) for the management of HER2-low breast cancer. Additionally, Prof Dent highlights the effect of estrogen deprivation therapy combined with endocrine therapy in young woman and the impact on cardiovascular health in the long-term, which is under investigation in the ongoing Phase 0 CROWN (NCT05309655) clinical study. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.